DE69031309D1 - Zusammensetzung zur steigerung der hautdurchlässigkeit - Google Patents

Zusammensetzung zur steigerung der hautdurchlässigkeit

Info

Publication number
DE69031309D1
DE69031309D1 DE69031309T DE69031309T DE69031309D1 DE 69031309 D1 DE69031309 D1 DE 69031309D1 DE 69031309 T DE69031309 T DE 69031309T DE 69031309 T DE69031309 T DE 69031309T DE 69031309 D1 DE69031309 D1 DE 69031309D1
Authority
DE
Germany
Prior art keywords
compositions
pleasure
composition
skin
increasing skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69031309T
Other languages
English (en)
Other versions
DE69031309T2 (de
Inventor
Chia-Ming Chiang
Gary Cleary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Cygnus Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23276050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69031309(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cygnus Therapeutic Systems filed Critical Cygnus Therapeutic Systems
Application granted granted Critical
Publication of DE69031309D1 publication Critical patent/DE69031309D1/de
Publication of DE69031309T2 publication Critical patent/DE69031309T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Amplifiers (AREA)
DE69031309T 1989-03-22 1990-03-19 Zusammensetzung zur steigerung der hautdurchlässigkeit Expired - Lifetime DE69031309T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/327,312 US4973468A (en) 1989-03-22 1989-03-22 Skin permeation enhancer compositions
PCT/US1990/001469 WO1990011064A1 (en) 1989-03-22 1990-03-19 Skin permeation enhancer compositions

Publications (2)

Publication Number Publication Date
DE69031309D1 true DE69031309D1 (de) 1997-09-25
DE69031309T2 DE69031309T2 (de) 1998-01-08

Family

ID=23276050

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69031309T Expired - Lifetime DE69031309T2 (de) 1989-03-22 1990-03-19 Zusammensetzung zur steigerung der hautdurchlässigkeit

Country Status (12)

Country Link
US (1) US4973468A (de)
EP (1) EP0464150B1 (de)
JP (1) JP2550441B2 (de)
KR (1) KR950010324B1 (de)
AT (1) ATE156995T1 (de)
AU (1) AU629331B2 (de)
CA (1) CA2012875C (de)
DE (1) DE69031309T2 (de)
DK (1) DK0464150T3 (de)
ES (1) ES2106029T3 (de)
FI (1) FI914391A0 (de)
WO (1) WO1990011064A1 (de)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5229129A (en) * 1989-07-12 1993-07-20 Cygnus Therapeutic Systems Transdermal administration of lisuride
NZ237241A (en) * 1990-03-02 1993-11-25 Pharmetrix Corp Method for increasing the storage stability of physostigmine
WO1991015176A1 (en) * 1990-04-06 1991-10-17 Pharmetrix Corporation Device and method for enhanced administration of physostigmine
US5225198A (en) * 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
US5705185A (en) * 1991-09-25 1998-01-06 Beta Pharmaceuticals Co. Transdermal delivery of estradiol and process for manufacturing said device
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5453279A (en) * 1992-04-21 1995-09-26 Tbs Laboratories, Inc. Enhancing transdermal absorption compositions; transdermal dosage form; and process
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
JPH0827003A (ja) * 1994-07-22 1996-01-30 Sekisui Chem Co Ltd 経皮吸収製剤
DK0781122T3 (da) * 1994-09-14 2000-10-30 Minnesota Mining & Mfg Matrix til transdermal lægmiddelafgivelse
GB9500116D0 (en) * 1995-01-05 1995-03-01 Ciba Geigy Ag Pharmaceutical compositions
US5573778A (en) * 1995-03-17 1996-11-12 Adhesives Research, Inc. Drug flux enhancer-tolerant pressure sensitive adhesive composition
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US6572879B1 (en) * 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
EP2921111A1 (de) 1995-08-29 2015-09-23 Nitto Denko Corporation Mikroporation der menschlichen Haut zur Arzneimittelabgabe und Überwachungsanwendungen
DE19548332A1 (de) * 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
WO1997034607A1 (en) * 1996-03-20 1997-09-25 Glaxo Group Limited Topical formulations of aciclovir
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
AU4990797A (en) * 1996-10-24 1998-05-15 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
AU718811B2 (en) * 1996-10-30 2000-04-20 Theratech, Inc. Fatty acid esters of glycolic acid and its salts as permeation enhancers
KR100294084B1 (ko) * 1998-06-02 2001-09-22 성재갑 비-스테로이드성소염진통제의경피흡수투여용조성물및이를포함하는경피흡수투여용제형
KR100215027B1 (ko) * 1997-01-27 1999-08-16 성재갑 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US6267984B1 (en) 1997-12-22 2001-07-31 Alza Corporation Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
ES2284248T3 (es) * 1998-04-27 2007-11-01 Astellas Pharma Inc. Formulacion farmaceutica en gel que comprende un compuesto triciclico (fk-506/tacrolimus).
FR2761600B1 (fr) 1998-06-19 2000-03-31 Oreal Composition moussante pour le lavage et le traitement des cheveux et/ou du cuir chevelu a base d'un principe actif, d'un tensioactif anionique, d'un tensioactif amphotere et d'un agent propenetrant
GB9825402D0 (en) † 1998-11-19 1999-01-13 Pfizer Ltd Antiparasitic formulations
US20030078499A1 (en) * 1999-08-12 2003-04-24 Eppstein Jonathan A. Microporation of tissue for delivery of bioactive agents
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
KR100856523B1 (ko) * 2000-08-03 2008-09-04 안타레스 파르마 아이피엘 에이쥐 충분한 치료효과를 보장하는 활성 화합물의 경피 및/또는경점막 투여용 신규 조성물
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US8728445B2 (en) 2001-05-01 2014-05-20 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences Hydrogel Compositions
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
DE60239528D1 (de) 2001-05-01 2011-05-05 Corium International Redwood City Zweiphasige, wasserabsorbierende bioadhäsive zusammenstezung
MXPA04005023A (es) * 2001-11-29 2004-08-11 3M Innovative Properties Co Formulaciones farmaceuticas que comprenden un modificador de respuesta inmune.
DE10159120B4 (de) * 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US8116860B2 (en) 2002-03-11 2012-02-14 Altea Therapeutics Corporation Transdermal porator and patch system and method for using same
WO2003101507A2 (en) 2002-03-11 2003-12-11 Altea Therapeutics Corporation Transdermal drug delivery device, method and use
US9918665B2 (en) 2002-03-11 2018-03-20 Nitto Denko Corporation Transdermal porator and patch system and method for using same
US20030199584A1 (en) * 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DK1530469T3 (da) * 2002-08-20 2009-05-04 Euro Celtique Sa Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
EP1556501A4 (de) 2002-10-28 2009-04-08 Transform Pharmaceuticals Inc Transdermaler assay mit magnetischerklemme
ES2239196T3 (es) * 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
CA2729967C (en) * 2002-12-13 2018-01-16 Schering-Plough Healthcare Products, Inc. Use of a transdermal or transmucosal ingredient delivery device
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US20040241223A1 (en) * 2003-05-27 2004-12-02 David Wong Oral dosage forms for macromolecular drugs
US7576226B2 (en) * 2003-06-30 2009-08-18 Richter Gedeon Vegyeszeti Gyar Rt. Process of making isomers of norelgestromin and methods using the same
CA2530996C (en) 2003-07-03 2013-05-07 Corium International, Inc. Wound dressing, ingredient delivery device and iv hold-down, and method relating to same
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
JP5619337B2 (ja) * 2003-10-10 2014-11-05 フェリング ビー．ブイ． 皮膚残渣を最小限に抑えるための経皮的医薬製剤
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
US7105263B2 (en) * 2003-12-30 2006-09-12 Samsung Electronics Company Dry toner comprising encapsulated pigment, methods and uses
KR20070007299A (ko) 2004-01-30 2007-01-15 코리움 인터네셔널, 인크. 활성제의 전달을 위한 급속 용해 필름
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
JP2008506701A (ja) * 2004-07-15 2008-03-06 フリーダム−２・エル・エル・シー 改変された組織マーキング顔料および組織マーキング顔料を改変するための方法
CN103497713B (zh) 2004-08-05 2018-07-17 考里安国际公司 粘合剂组合物
US8258305B2 (en) 2005-02-23 2012-09-04 Prexa Pharmaceuticals, Inc. Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
DE102006050558B4 (de) * 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
US20100278935A1 (en) * 2007-07-30 2010-11-04 Stacey William C Immune System Modulator Formulation
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
US8609733B2 (en) * 2008-05-19 2013-12-17 Massachusetts Institute Of Technology Sensory-specific local anesthesia and prolonged duration local anesthesia
US8658699B2 (en) * 2008-05-19 2014-02-25 Massachusetts Institute Of Technology Chemical permeation enhancers enhance nerve blockade by toxins
WO2010083035A2 (en) 2009-01-14 2010-07-22 Corium International, Inc. Transdermal administration of tamsulosin
US9041541B2 (en) 2010-01-28 2015-05-26 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
WO2010101625A2 (en) 2009-03-02 2010-09-10 Seventh Sense Biosystems, Inc. Oxygen sensor
US20100256524A1 (en) * 2009-03-02 2010-10-07 Seventh Sense Biosystems, Inc. Techniques and devices associated with blood sampling
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
WO2011000210A1 (zh) * 2009-07-01 2011-01-06 润和生物医药科技(汕头)有限公司 促渗剂组合物及其透皮给药系统中的应用
EP2461813A4 (de) 2009-08-05 2014-02-19 Univ Wake Forest Health Sciences Zusammensetzungen und verfahren zur apoptose-herbeiführung in prostatakrebszellen
WO2011143657A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
WO2011163347A2 (en) 2010-06-23 2011-12-29 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
JP2013538069A (ja) 2010-07-16 2013-10-10 セブンス センス バイオシステムズ，インコーポレーテッド 流体移動デバイスのための低圧環境
US20130158482A1 (en) 2010-07-26 2013-06-20 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
WO2012021801A2 (en) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systems and techniques for monitoring subjects
US8808202B2 (en) 2010-11-09 2014-08-19 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
EP2701601B1 (de) 2011-04-29 2017-06-07 Seventh Sense Biosystems, Inc. Vorrichtungen und verfahren zur sammlung und/oder manipulation von blutspuren oder anderen körperflüssigkeiten
CN103874460B (zh) 2011-04-29 2016-06-22 第七感生物系统有限公司 一种用于从受验者的皮肤接收血液或其它物质的装置
EP3106092A3 (de) 2011-04-29 2017-03-08 Seventh Sense Biosystems, Inc. Systeme und verfahren zur flüssigkeitsentnahme aus einer person
SG11201400167VA (en) * 2011-08-25 2014-06-27 Nipro Patch Co Ltd Hydrous adhesive skin patch
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6342334B2 (ja) * 2012-01-26 2018-06-13 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 経皮ホルモン補充療法
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) * 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10258682B2 (en) 2013-01-16 2019-04-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Attenuated chlamydia vaccine
NZ710890A (en) 2013-03-15 2016-11-25 Childrens Medical Ct Corp Neosaxitoxin combination formulations for prolonged local anesthesia
CA2908434C (en) 2013-04-07 2021-12-28 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
MX2016006678A (es) 2013-11-22 2016-09-13 Genzyme Corp Nuevos metodos para tratar enfermedades neurodegenerativas.
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (de) 2013-12-20 2016-10-26 The Broad Institute, Inc. Kombinationstherapie mit neoantigen-impfstoff
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3234193B1 (de) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molekulare biomarker für krebsimmuntherapie
EP3297660A2 (de) 2015-05-20 2018-03-28 The Broad Institute Inc. Gemeinsam genutzte neoantigene
WO2017004507A1 (en) * 2015-07-02 2017-01-05 Noven Pharmaceuticals, Inc. Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3923989A (en) * 1973-07-13 1975-12-02 Sandoz Ag Nitro substituted picolinonitriles as anti-bacterial and anti-fungal agents
US4006218A (en) * 1974-07-08 1977-02-01 Johnson & Johnson Potentiated medicaments
US3926188A (en) * 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4440771A (en) * 1982-02-12 1984-04-03 The United States Of America As Represented By The Secretary Of The Army 2-Acetyl quinoline thiosemicarbazones useful in treatment of gonorrhea, malaria or bacterial infections
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
FR2542998B1 (fr) * 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
US4559222A (en) * 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4717568A (en) * 1985-08-09 1988-01-05 Alza Corporation Laminar arrangement for increasing delivery of beneficial agent from dispenser
ZA87332B (en) * 1986-02-27 1987-08-26 Warner Lambert Co Compositions containing fixed combinations
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
AU601528B2 (en) * 1986-12-22 1990-09-13 Ortho-Mcneil Pharmaceutical, Inc. Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
CN1021196C (zh) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
CH674618A5 (de) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US4783450A (en) * 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US4764379A (en) * 1987-08-24 1988-08-16 Alza Corporation Transdermal drug delivery device with dual permeation enhancers

Also Published As

Publication number Publication date
CA2012875A1 (en) 1990-09-22
FI914391A0 (fi) 1991-09-18
ES2106029T3 (es) 1997-11-01
DE69031309T2 (de) 1998-01-08
JP2550441B2 (ja) 1996-11-06
AU629331B2 (en) 1992-10-01
KR950010324B1 (ko) 1995-09-14
EP0464150A1 (de) 1992-01-08
AU5417490A (en) 1990-10-22
EP0464150B1 (de) 1997-08-20
DK0464150T3 (da) 1997-09-15
JPH04505157A (ja) 1992-09-10
US4973468A (en) 1990-11-27
ATE156995T1 (de) 1997-09-15
WO1990011064A1 (en) 1990-10-04
CA2012875C (en) 1995-12-05
KR920700601A (ko) 1992-08-10
EP0464150A4 (en) 1993-04-14

Similar Documents

Publication Publication Date Title
DE69031309D1 (de) Zusammensetzung zur steigerung der hautdurchlässigkeit
PT99749A (pt) Processo de preparacao de uma composicao incrementadora da permeacao na pele
AU6670998A (en) Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
DE60021059D1 (de) Hydrogelpartikel formulierungen
DK0429039T3 (da) Anvendelse af en opiat-antagonist til fremstilling af en farmaceutisk sammensætning, der skal indgives transdermalt, samt organ til transdermal afgivelse
MX9708722A (es) Metodos y composiciones para mejorar la permeacion de la piel a los farmacos utilizando mejoradores de la permeacion, cuando los farmacos y/o los mejoradores de la permeacion son inestables en combinacion durante el almacenamiento a largo plazo.
KR850004389A (ko) 경피침투가 증진된 생리학적 활성제제의 제조방법
ATE288744T1 (de) Arzneiformulierungen zur hormonersatztherapie zur topischen anwendung auf der haut
DE69833000D1 (de) Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen
EA200400242A1 (ru) Фармацевтические композиции, содержащие бета-лапахон или его производные или аналоги, и способы их применения
NO303527B1 (no) Ïstrogenholdig medikament og anordning for transdermal administrering derav
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
BR0108930A (pt) Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente
EP0857488A1 (de) Verfahren und Zusammensetzungen zur Erhöhung des Hautdurchtritts von Arzneistoffen unter Verwendung von Permeationsbeschleunigern
HUP0302452A2 (hu) Prosztaglandin E1-et tartalmazó topikus gyógyászati készítmények
DE69735656D1 (de) Neue Formulierungen zur transdermale Verabreichung von Fluoxetin
KR970706021A (ko) N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형제제(MEDICINAL ADJUVANTS CONSISTIONG OF AN N-SUBSTITUED-o-TOLUIDING DERIVANTIVE, AND PERCUTANEOUSLY ABSORBALE PREPARATIONS COMPRISING THE ADJUVANTS)
EP0971708B1 (de) Nimesulidhaltige gelsysteme zur topischen anwendung
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
ES421570A1 (es) Un procedimiento para la preparacion de nuevos derivados de cianopregnenona.
ATE212222T1 (de) Zusammensetzungen zur transdermalen und dermalen verabreichung von biologisch wirksamen stoffen
DE69918124D1 (de) Formulierungen zur transdermalen verabreichung von fenoldopam
KR890003362A (ko) 침투 증진 조성물
KR950002749A (ko) 0차 흡수속도를 갖는 지속성 경피투여 제형 및 그 제조방법
KR960021036A (ko) 콜치신을 유효성분으로 함유하는 항간독성 조성물 및 그 제조방법

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: ORTHO-MCNEIL PHARMACEUTICAL, INC., RARITAN, N.J.,

8328 Change in the person/name/address of the agent

Free format text: BOEHMERT & BOEHMERT, 80336 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN